work
investig
formul
vivo
efficaci
dendrit
cell
dc
target
plasmid
dna
load
biotinyl
chitosan
nanoparticl
nasal
immun
nucleocapsid
n
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
antigen
induct
antigenspecif
mucos
system
immun
respons
site
viru
entri
major
challeng
vaccin
design
design
strategi
noninvas
receptor
mediat
gene
deliveri
nasal
resid
dc
pdna
load
biotinyl
chitosan
nanoparticl
prepar
use
complex
coacerv
process
character
size
shape
surfac
charg
plasmid
load
protect
nucleas
digest
pdna
load
biotinyl
chitosan
nanoparticl
target
bifunct
fusion
protein
bffp
vector
achiev
dc
select
target
bffp
recombin
fusion
protein
consist
truncat
corestreptavidin
fuse
singl
chain
antibodi
scfv
corestreptavidin
arm
fusion
protein
bind
biotinyl
nanoparticl
scfv
impart
target
specif
dc
receptor
demonstr
intranas
administr
bffp
target
formul
along
dc
matur
stimuli
enhanc
magnitud
mucos
iga
well
system
igg
n
protein
strategi
led
detect
augment
level
n
protein
specif
system
igg
nasal
iga
antibodi
howev
follow
intranas
deliveri
nake
pdna
mucos
system
immun
respons
detect
parallel
comparison
target
formul
use
intramuscular
intranas
rout
show
intramuscular
rout
superior
induct
system
igg
respons
compar
intranas
rout
result
suggest
target
pdna
deliveri
noninvas
intranas
rout
strategi
design
lowdos
vaccin
dendrit
cell
dc
special
antigenpres
cell
apc
play
key
role
immun
respons
antigen
uptak
process
present
among
apc
dc
consid
effici
cell
induct
regul
immun
respons
variou
strategi
employ
har
dc
select
target
vaccin
antigen
shown
enorm
potenti
preclin
stage
design
lowdos
vaccin
dc
express
larg
number
endocyt
receptor
ctype
lectin
receptor
clr
recogn
uptak
pathogen
differ
strategi
employ
target
deliveri
antigen
dc
util
help
antibodi
natur
ligand
dc
restrict
crl
antigen
target
clr
result
augment
immun
respons
dosespar
antigen
skew
immun
respons
among
clr
dc
ctype
lectin
receptor
cd
receptor
best
character
member
type
ctype
lectin
receptor
famili
primarili
express
immatur
dc
skin
lymph
node
spleen
intracellular
rout
target
antigen
enhanc
load
present
antigen
peptid
mhc
class
class
ii
molecul
lead
prime
antigen
specif
cell
respect
vivo
target
antigen
murin
receptor
along
matur
stimuli
shown
augment
effici
antigen
present
tcell
achiev
dc
select
target
biotinyl
protein
antigen
previous
develop
quadroma
hybridhybridoma
base
full
length
bispecif
monoclon
antibodi
bsmab
full
length
hybridhybridoma
base
bsmab
bind
biotinyl
antigen
one
arm
target
arm
target
biotinyl
ovalbumin
ova
use
bsmab
reduc
dose
antigen
compar
non
target
antigen
howev
quadroma
produc
bsmab
along
parent
unwant
heavi
light
chain
combin
result
lower
yield
addit
antibodybas
biotin
bind
sever
order
weaker
streptavidin
bind
consequ
overcom
inher
limit
associ
bsmab
design
recombin
bifunct
fusion
protein
bffp
vector
dc
target
singl
chain
variabl
fragment
scfv
recogn
mous
dc
dec
fuse
truncat
corestreptavidin
domain
express
escherichia
coli
use
express
system
truncat
corestreptavidin
arm
bind
biotinyl
antigen
scfv
impart
target
specif
dc
receptor
use
bffp
demonstr
vivo
target
four
differ
class
biotinyl
antigen
name
protein
peptid
gangliosid
plasmid
dna
lowdos
vaccin
vivo
studi
mice
biotinyl
ova
shown
presenc
bffb
mab
humor
cellmedi
respons
augment
target
formul
low
concentr
antigen
ng
salin
adequ
achiev
strong
immun
respons
mice
multipl
antigen
target
strategi
also
achiev
enhanc
humor
cellmedi
respons
biotinyl
ova
sar
spike
ebola
glycoprotein
peptid
anthrax
protect
antigen
herein
select
nucleocapsid
n
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
vaccin
antigen
sarscov
contain
four
major
structur
protein
membran
spike
envelop
e
nucleocapsid
n
studi
shown
n
protein
highli
conserv
compar
protein
e
therefor
could
serv
stabl
vaccin
candid
furthermor
n
protein
abundantli
shed
sar
infect
n
protein
specif
antibodi
memori
cell
detect
sarsrecov
patient
number
studi
use
recombin
n
protein
dna
encod
n
protein
vaccin
antigen
elicit
humor
cellular
immun
respons
anim
model
context
select
plasmid
dna
encod
n
protein
pvaxn
vaccin
antigen
chitosan
dna
deliveri
vehicl
chitosan
natur
polysaccharid
consist
repeat
dglucosamin
nacetyldglucosamin
unit
link
via
glycosid
bond
chitosan
deriv
ideal
nucleic
acid
deliveri
vehicl
due
excel
biocompat
biodegrad
nontox
natur
presenc
high
cation
charg
chitosan
provid
strong
bind
affin
nucleic
acid
result
excel
gene
deliveri
vehicl
aim
present
work
develop
character
dendrit
cell
target
chitosan
nanoparticl
vaccin
deliveri
system
via
nasal
rout
murin
respiratori
dc
subset
airway
dc
alveolar
dc
express
receptor
respiratori
dc
could
serv
primari
target
uptak
target
nanoparticl
strategi
combin
pdna
carri
capac
chitosan
select
target
specif
bffp
respiratori
dc
ultrapur
water
solubl
biotinyl
chitosan
hydrochlorid
use
formul
pvaxn
load
nanoparticl
pvaxn
load
biotinyl
chitosan
nanoparticl
surfac
function
bifunct
fusion
protein
achiev
nasal
dc
target
figur
differ
np
formul
tabl
given
intranas
intramuscular
mice
elicit
immun
respons
result
immun
respons
present
ultrapur
chitosan
hydrochlorid
salt
protasan
cl
purchas
fmc
biopolym
novamatrix
norway
vector
lipofectamin
invitrogen
usa
biotinamidohexano
acid
ester
sodium
salt
sulphonhslcbiotin
iptg
chitosanas
streptomyc
griseu
lysozym
purchas
sigmaaldrich
oakvil
canada
ninta
agaros
resin
qiagen
mississauga
canada
rat
antimous
mab
purifi
hybridoma
kind
gift
dr
gold
univers
british
columbia
canada
tmb
tetramethylbenzidin
peroxidas
substrat
kirkegaard
perri
laboratori
inc
gaitherburg
md
hrp
base
mous
antibodi
isotyp
kit
obtain
southern
biotech
birmingham
al
usa
african
green
monkey
transform
kidney
cell
american
type
cultur
collect
atcc
dulbecco
modifi
eagl
medium
dmem
penicillinstreptomycinlglutamin
psg
fetal
bovin
serum
fb
procur
gibco
burlington
canada
sarscov
nucleocapsid
n
dna
sequenc
polymeras
chain
reaction
pcr
amplifi
use
pfastbacnp
dna
templat
gene
specif
primer
primer
contain
bamhi
restrict
site
kozak
translat
initi
sequenc
initi
codon
atg
primer
contain
stop
codon
ecori
restrict
site
pcr
fragment
electrophores
low
melt
point
agaros
gel
gelpurifi
use
qiagen
gel
extract
kit
purifi
fragment
doubl
digest
bamhi
ecori
gel
purifi
purifi
fragment
ligat
bamhi
ecori
digest
mammalian
express
vector
invitrogen
usa
ligat
mixtur
transform
e
coli
cell
heat
shock
method
plate
onto
lb
agar
plate
contain
kanamycin
recombin
posit
clone
screen
plasmid
dna
isol
use
qiagen
plasmid
dna
isol
kit
restrict
digest
fragment
map
result
plasmid
design
pvaxn
use
present
studi
pvaxn
use
experi
purifi
use
endofre
plasmid
mega
kit
qiagen
mississauga
canada
confirm
express
encod
nprotein
cell
grown
dmem
medium
supplement
fb
psg
cell
seed
densiti
per
well
plate
grown
overnight
confluenc
next
day
cell
transfect
pvaxn
use
lipofectamin
reagent
per
manufact
instruct
allow
grow
hr
humidifi
co
atmospher
cell
trypsin
pellet
pellet
wash
twice
pb
lyse
ripa
buffer
mm
nacl
mm
tri
ph
sd
triton
sodium
deoxychol
mm
edta
cell
lysat
clear
centrifug
min
rpm
clear
lysat
analyz
use
reduc
sd
page
subsequ
protein
electrophoret
transfer
nitrocellulos
membran
membran
block
skim
milk
probe
antisarsn
protein
monoclon
antibodi
previous
develop
lab
final
unbound
antibodi
wash
membran
incub
goat
antimous
igg
hrpo
blot
develop
ecl
plu
western
blote
reagent
amersham
pharmacia
biotech
baiedurf
canada
chitosan
hydrochlorid
biotinyl
use
biotinamidohexano
acid
ester
sodium
salt
sulfonhslcbiotin
briefli
chitosan
solut
mgml
prepar
pb
ph
biotinyl
initi
ad
mg
sulfonhslcbiotin
reaction
carri
h
room
temperatur
biotinyl
chitosan
dialyz
pb
overnight
lyophil
hr
extent
amin
group
modif
glucosamin
monom
chitosan
determin
verifi
attach
biotin
percentag
biotin
substitut
primari
amin
group
glucosamin
monom
determin
fluorescamin
assay
aqueou
solut
plain
biotinyl
chitosan
made
variou
concentr
wv
respect
chitosan
solut
ad
triplic
black
fluoresc
micropl
fluorescamin
wv
anhydr
dmso
ad
incub
min
fluoresc
intens
record
use
synergi
fluoresc
plate
reader
biotek
instrument
winooski
vt
nm
nm
bandwidth
excit
filter
nm
nm
bandwidth
emiss
filter
sensit
set
plasmid
dna
pvaxn
load
biotinyl
chitosan
nanoparticl
np
prepar
use
modifi
complex
coacerv
method
describ
previous
condit
formul
complex
chitosan
pvaxn
optim
briefli
biotinyl
chitosan
dissolv
sodium
acet
buffer
mm
ph
obtain
final
concentr
wv
pass
syring
filter
obtain
differ
weight
ratio
chitosan
dna
pvaxn
solut
prepar
differ
concentr
mgml
sodium
sulphat
mm
chitosan
dna
solut
separ
preheat
water
bath
biotinyl
chitosan
mgml
mm
sodium
acet
buffer
ph
solut
ad
pvaxn
solut
mixtur
immedi
vortex
second
particl
left
room
temperatur
minut
stabil
stabil
np
centrifug
rpm
minut
supernat
analyz
presenc
free
dna
absorb
nm
use
nanodrop
nanodrop
technolog
inc
wilmington
delawar
analysi
encapsul
effici
dna
encapsul
effici
calcul
use
formula
encapsul
effici
ee
aba
total
dna
amount
b
free
dna
supernat
complex
format
chitosan
dna
analyz
electrophoret
gel
mobil
assay
sampl
np
prepar
weight
ratio
biotinyl
chitosan
pvaxn
dna
mix
load
dye
load
agaros
gel
contain
ethidium
bromid
gel
immers
trisacetateedta
buffer
expos
v
min
dna
band
visual
use
alpha
imag
alpha
innotech
san
leandro
ca
unless
otherwis
mention
np
prepar
biotinyl
chitosan
pvaxn
weight
ratio
use
studi
size
zeta
potentialth
particl
size
zeta
potenti
pvaxn
load
biotinyl
chitosan
nanoparticl
measur
use
zetas
malvern
uk
measur
mean
size
diamet
nanoparticl
base
dynam
light
scatter
techniqu
zeta
potenti
measur
nanoparticl
suspend
deionis
water
measur
perform
automat
mode
see
whether
nanoencapsul
pvaxn
protect
nucleas
digest
nanoparticl
encapsul
pvaxn
nake
pvaxn
subject
dnase
digest
briefli
nake
pvaxn
nanoencapsul
pvaxn
deionis
water
incub
u
dnase
invitrogen
min
dnase
activ
stop
ad
edta
solut
final
concentr
mm
altern
follow
incub
dnase
integr
plasmid
dna
within
particl
analyz
lysi
particl
chitosanas
lysozym
briefli
treatment
dnase
min
np
centrifug
wash
three
time
remov
dnase
resuspend
naachoac
buffer
mm
digest
np
incub
chitosanas
uml
lysozym
uml
hr
integr
dna
sampl
analyz
agaros
gel
use
alpha
imag
alpha
innotech
san
leandro
ca
express
purif
bifunct
fusion
protein
bffp
specif
scfv
fuse
truncat
core
streptavidin
describ
previou
commun
slight
modif
briefli
vector
transform
ripl
e
coli
cell
stratagen
cedar
creek
tx
use
heat
shock
method
e
coli
transform
cultur
medium
contain
ampicillin
chloramphenicol
induc
mm
iptg
follow
induct
cultur
grown
hr
harvest
centrifug
periplasm
cytoplasm
solubl
bffp
extract
bugbust
master
mix
reagent
novagen
inc
accord
manufactur
instruct
lysat
clear
centrifug
load
onto
ninta
agaros
purif
periplasm
solubl
protein
perform
use
immobil
metal
affin
chromatographi
imac
imac
fraction
analyz
puriti
sdspage
reduc
condit
stain
coomassi
brilliant
blue
figur
support
inform
express
purif
full
length
sarscov
n
protein
carri
accord
publish
method
briefli
full
length
n
protein
gene
codon
optim
high
level
bacteri
express
chemic
synthes
geneart
inc
n
protein
express
insolubl
inclus
bodi
top
e
coli
strain
purifi
denatur
condit
use
imac
column
refold
purifi
refold
fraction
n
protein
analyz
sd
page
reduc
condit
figur
recombin
fulllength
n
protein
use
antigen
analyz
magnitud
antibodi
respons
recal
antigen
stimul
splenocyt
ten
twelv
week
old
femal
balbc
mice
use
studi
procur
charl
river
laboratori
inc
canada
anim
hous
health
scienc
laboratori
anim
servic
hsla
univers
alberta
edmonton
canada
anim
treatment
care
euthanasia
carri
accord
canadian
council
anim
care
guidelin
total
five
mice
per
group
use
evalu
immun
respons
vaccin
construct
mice
immun
either
intranas
intramuscular
rout
day
day
variou
combin
tabl
dose
pvaxn
administ
solubl
np
bffp
target
np
presenc
absenc
dc
matur
stimuli
anticd
mab
intranas
deliveri
mice
held
vertic
posit
perpendicular
bench
hold
tightli
vertic
posit
vaccin
formul
nostril
deliv
drop
wise
pipett
tip
right
nostril
appli
volum
natur
inhal
adequ
care
taken
assur
proper
deliveri
drop
nostril
avoid
incid
swallow
follow
administr
formul
mice
held
vertic
posit
time
ensur
proper
deliveri
intramuscular
administr
done
inject
vaccin
formul
gaug
needl
quadricep
muscl
total
volum
igg
titer
evalu
use
recombin
n
protein
tail
vain
bleed
perform
day
termin
bleed
day
collect
cardiac
punctur
follow
co
asphyxi
cervic
disloc
nasal
wash
perform
immedi
cardiac
punctur
briefli
trachea
mous
open
fine
micropipettor
tip
insert
nasal
fluid
collect
flush
pb
contain
bsa
wv
nasal
caviti
wash
collect
nostril
nasal
wash
kept
till
day
analysi
sar
n
protein
specif
igg
iga
titer
evalu
use
enzymelink
immunosorb
assay
elisa
nunc
maxisorp
flatbottom
elisa
micropl
coat
n
protein
solut
overnight
follow
day
plate
wash
three
time
pbst
tween
pb
ph
block
bsa
solut
hr
plate
wash
pbst
dilut
serum
mous
ad
duplic
incub
overnight
plate
wash
pbst
goatantimous
igg
hrp
ad
follow
incub
hr
plate
wash
pbst
final
tmb
substrat
ad
minut
optic
densiti
measur
nm
use
elisa
vmax
kinet
micropl
reader
molecular
devic
corp
ca
nasal
iga
level
serum
isotyp
igg
igg
nprotein
determin
use
respect
isotyp
southern
biotechnolog
birmingham
al
procedur
describ
follow
except
end
hrpo
dilut
iga
hrpo
dilut
ad
plate
analyz
n
protein
specif
iga
content
nasal
wash
abt
substrat
prepar
per
manufactur
instruct
ad
plate
optic
densiti
record
nm
cytokin
assayspleen
group
mice
pool
cell
suspens
splenocyt
prepar
disrupt
spleen
frost
slide
splenocyt
pass
cell
strainer
obtain
singl
cell
suspens
red
blood
cell
lyse
ack
lysi
buffer
cell
wash
twice
serum
free
media
final
splenocyt
resuspend
complet
dmem
medium
cell
densiti
adjust
ml
splenocyt
seed
densiti
well
stimul
n
protein
concanavalin
con
posit
control
media
sham
control
cultur
supernat
harvest
hr
incub
humidifi
atmospher
co
level
cytokin
content
supernat
analyz
cytokin
elisa
kit
use
corn
micropl
per
manufactur
instruct
statist
analysisdata
present
mean
standard
deviat
sd
throughout
manuscript
statist
signific
differ
test
use
one
way
anova
test
turkey
multipl
comparison
test
signific
level
set
statist
differ
denot
p
ns
signific
differ
p
data
analysi
perform
use
graphpad
prism
version
graphpad
softwar
inc
la
jolla
ca
usa
dna
vaccin
vector
use
construct
insert
full
length
sarscov
n
protein
gene
sequenc
bamhi
ecori
restrict
site
mammalian
express
vector
obtain
pvaxn
recombin
posit
clone
isol
kanamycin
select
pressur
screen
plasmid
dna
isol
use
plasmid
dna
isol
kit
qiagen
restrict
digest
fragment
map
dna
sequenc
integr
pvaxn
construct
evalu
use
agaros
gel
analysi
figur
confirm
express
encod
antigen
pvaxn
dna
encod
n
protein
transient
transfect
cell
use
lipofectamin
transient
express
n
protein
detect
western
blot
use
antinprotein
monoclon
antibodi
previous
develop
lab
result
western
blot
confirm
express
n
protein
specif
band
cell
lysat
mock
transfect
cell
show
crossreact
antibodi
lane
figur
water
solubl
chitosan
hydrochlorid
salt
biotinyl
long
chain
water
solubl
sulfonhydroxysuccinimid
ester
deriv
biotin
incorpor
extend
spacer
arm
provid
hexano
acid
spacer
arm
improv
interact
avidin
biotinyl
macromolecul
overcom
steric
hindranc
biotin
bind
site
avidin
figur
extent
biotinyl
ie
substitut
primari
amin
group
glucosamin
amin
group
chitosan
determin
use
fluorescamin
assay
fluorescamin
reagent
react
rapidli
primari
amin
use
estim
magnitud
substitut
primari
amin
group
excit
nm
wavelength
fluoresc
primari
aminedy
complex
emiss
wavelength
approxim
nm
decreas
fluoresc
intens
biotinyl
chitosan
correl
obtain
percentag
substitut
biotin
amin
group
chitosan
backbon
result
show
overal
extent
glucosamin
modif
found
percent
compar
plain
chitosan
hydrochlorid
figur
chitosan
concentr
wv
show
highest
decreas
fluoresc
intens
therefor
label
biotin
sampl
use
subsequ
experi
nanoparticl
formul
use
modifi
complex
coacerv
neg
charg
pvaxn
dna
posit
charg
biotinyl
chitosan
agaros
gel
analysi
perform
determin
optim
weight
ratio
biotinyl
chitosan
plasmid
dna
achiev
maximum
encapsul
effici
figur
result
agaros
gel
show
weight
ratio
biotinyl
chitosan
plasmid
dna
yield
maximum
effici
complex
almost
neglig
free
plasmid
dna
load
effici
weight
ratio
biotinyl
chitosan
plasmid
dna
effici
consist
encapsul
effici
pvaxn
found
rang
determin
nanodrop
experi
next
pvaxn
load
biotinyl
chitosan
nanoparticl
character
size
surfac
charg
load
effici
averag
hydrodynam
diamet
nanoparticl
determin
zetas
found
nm
zeta
potenti
mv
result
nucleas
protect
assay
suggest
nanoencapsul
pvaxn
could
protect
high
concentr
dnase
digest
lane
figur
turn
nake
pvaxn
complet
degrad
dnase
digest
lane
figur
dnase
treat
np
digest
chitosanas
lysozym
result
releas
intact
dna
show
sign
degrad
lane
figur
suggest
formul
process
affect
integr
nanoencapsul
dna
nucleas
protect
dna
chitosan
nanoparticl
would
meaning
mainten
integr
function
dna
vaccin
dendrit
cell
target
vector
bffp
express
purifi
periplasm
solubl
protein
per
previou
publish
method
modif
construct
encod
scfvcorestreptavidin
fusion
protein
bffp
subject
medium
scale
express
express
bffp
verifi
use
mab
western
blot
bacteri
cell
pellet
lyse
bug
buster
master
mix
reagent
effici
extract
periplasm
cytoplasm
solubl
protein
bffp
purifi
lysat
use
imac
column
gradient
immidazol
concentr
nativ
protein
elut
buffer
figur
final
yield
bffp
found
approxim
mgl
induc
bacteri
cultur
prokaryot
fulllength
sarscov
n
protein
use
antigen
analyz
antibodi
titer
recal
antigen
stimul
splenocyt
nprotein
ctermin
tag
express
purifi
inclus
bodi
denatur
condit
figur
accord
previou
protocol
pvaxn
load
biotinyl
chitosan
nanoparticl
append
bffp
dec
restrict
dc
target
evalu
vivo
potenti
elicit
immun
respons
follow
nasal
administr
posit
control
formul
also
administ
intramuscular
rout
tabl
addit
bffp
target
biotinyl
nanoparticl
compar
immun
respons
presenc
absenc
dc
matur
stimuli
antimous
mab
agonist
mab
bind
dc
result
activ
cell
replac
signal
via
cell
mab
use
adjuv
combin
target
protein
base
vaccin
effect
mucos
adjuv
upon
intranas
administr
combin
influenza
peptid
encapsul
liposom
vaccin
examin
system
immun
respons
elicit
use
target
vaccin
intranas
intramuscular
im
rout
presenc
n
protein
specif
igg
antibodi
analyz
indirect
elisa
serum
sampl
collect
differ
timepoint
day
serum
igg
profil
figur
show
nasal
administr
bffp
target
nanoparticl
combin
mab
elicit
higher
level
system
igg
compar
nake
dna
vaccin
formul
administ
im
rout
addit
bffp
target
nanoparticl
absenc
matur
stimuli
mab
elicit
significantli
lower
level
p
igg
titer
compar
bffp
target
nanoparticl
administ
along
anticd
mab
trend
observ
formul
administ
either
im
rout
expect
intramuscular
group
immun
target
nanoparticl
along
matur
stimuli
induc
highest
level
antibodi
titer
serum
titer
target
formul
npbffp
significantli
p
higher
nake
dna
formul
follow
intranas
well
intramuscular
administr
figur
addit
separ
set
experi
found
immun
respons
np
anticd
mab
significantli
lower
observ
target
np
anticd
mab
unpublish
result
interestingli
observ
n
protein
specif
igg
titer
follow
nasal
deliveri
nake
pvaxn
nanoparticl
encapsul
pvaxn
possibl
reason
could
lowdos
nake
nanoencapsul
dna
dna
pvaxn
administ
result
show
use
dc
target
ligand
bffp
presenc
matur
stimuli
lead
enhanc
immunogen
dna
vaccin
pdna
vaccin
could
provid
augment
serum
igg
titer
low
dose
serum
igg
isotyp
profil
specif
n
protein
follow
pdna
vaccin
irrespect
rout
administr
indic
target
formul
augment
level
intramuscular
rout
howev
found
superior
compar
nasal
rout
ratio
indic
bias
immun
respons
fig
mucos
surfac
rich
antigen
present
cell
dc
uptak
antigen
resid
dc
nasalassoci
lymphoid
tissu
nalt
necessari
induct
mucos
immun
respons
product
sar
n
protein
specif
mucos
iga
antibodi
could
vital
protect
sar
cov
infect
previou
studi
shown
mucos
iga
play
import
role
protect
sarscov
viru
anim
model
found
significantli
higher
mucos
iga
level
nasal
wash
follow
nasal
administr
dc
target
nanoparticl
combin
mab
compar
intranas
deliveri
pvaxn
np
bffp
target
np
p
fig
detect
mucos
iga
respons
also
observ
follow
intramuscular
administr
bffp
target
nanoparticl
alon
combin
mab
matur
signific
differ
respons
either
formul
ns
p
find
explain
base
previou
observ
system
administr
target
protein
vaccin
could
provid
protect
mucos
pathogen
howev
mere
detect
iga
respons
observ
follow
intramuscular
administr
pvaxn
formul
result
clearli
indic
chitosan
nanoparticl
administ
nasal
rout
effici
elicit
mucos
immun
respons
iga
level
thu
nasal
administ
dc
target
nanoparticl
provid
addit
advantag
mucos
immun
could
lead
neutral
pathogen
follow
exposur
observ
interest
sinc
sar
viru
primarili
infect
upper
respiratori
tract
induct
mucos
immun
mucos
iga
could
limit
viral
attach
pathogenesi
interferongamma
level
measur
determin
whether
intranas
intramuscular
administr
target
nontarget
vaccin
elicit
cellular
immun
recombin
n
protein
use
recal
antigen
concanvalin
con
serv
posit
control
media
treat
sham
control
shown
figur
splenocyt
group
mice
treat
target
formul
npbffp
secret
significantli
higher
level
stimul
n
protein
either
intranas
intramuscular
rout
vaccin
mice
target
chitosan
nanoparticl
mab
matur
stimuli
result
highest
level
secret
follow
target
chitosan
nanoparticl
without
matur
stimuli
p
non
target
nake
pdna
vaccin
formul
found
less
effect
provok
signific
level
detect
level
observ
splenocyt
cultur
treat
media
alon
wherea
high
level
pgml
present
follow
stimul
con
sar
emerg
infecti
diseas
caus
novel
coronaviru
name
sarscov
start
twenti
first
centuri
sar
outbreak
serious
threaten
healthcar
agenc
around
world
peopl
infect
result
death
till
date
therapeut
treatmentvaccin
avail
contain
futur
threat
sar
endem
pandem
sinc
sar
transmit
respiratori
rout
respiratori
tract
serv
common
rout
viru
entri
firstlin
defens
becom
mandatori
design
vaccin
deliveri
system
provid
antigen
specif
mucos
immun
respiratori
tract
harbour
local
dc
subset
routin
sampl
process
innocu
agent
henc
respiratori
tract
resid
dc
could
serv
ideal
target
uptak
target
nanoparticl
administ
noninvas
mean
previou
studi
shown
n
protein
highli
conserv
therefor
could
serv
stabl
vaccin
candid
howev
studi
perform
use
n
protein
antigen
base
system
immun
attempt
made
natur
mimic
rout
viral
infect
target
mucos
dc
logist
behind
target
pdna
vaccin
dc
stem
fact
tradit
intramuscular
rout
pdna
immun
result
express
antigen
myocyt
howev
myocyt
profession
antigen
present
cell
thu
present
antigen
though
mhc
class
pathway
furthermor
myocyt
migrat
drain
lymph
node
express
costimulatori
molecul
featur
essenti
requir
prime
activ
cell
therefor
main
object
work
investig
mucos
dc
target
potenti
pdna
load
chitosan
nanoparticl
mucos
deliveri
dna
vaccin
mimic
natur
mode
viru
infect
induc
humor
cellular
immun
respons
nake
dna
ineffect
cross
mucos
barrier
rapidli
degrad
nucleas
contemporari
effort
direct
improv
immunogen
dna
vaccin
wide
rang
strategi
adopt
literatur
increas
immunogen
profil
dna
vaccin
use
heterolog
primeboost
regim
coexpress
cytokin
electropor
use
viral
nonvir
gene
deliveri
vehicl
context
design
effect
mucos
pdna
deliveri
non
viral
vector
polymer
nanomicro
particl
liposom
protect
plasmid
dna
shown
better
immunogen
profil
system
specif
deliv
pdna
antigen
present
cell
dendrit
cell
macrophag
addit
deliveri
system
could
surfac
function
target
ligand
achiev
dcselect
target
deliveri
plasmid
dna
differ
immun
rout
numer
research
find
explor
nanomicro
particl
formul
use
chitosan
deriv
gene
deliveri
vehicl
chitosan
believ
show
better
nasal
deliveri
prospect
two
mechan
first
cation
charg
chitosan
confer
bind
neg
sialic
residu
mucu
line
nasal
epitheli
cell
therebi
slow
clearanc
secondli
chitosan
transient
open
tight
junction
allow
increas
paracellular
transport
across
nasal
mucosa
addit
attach
receptor
specif
ligand
chitosan
microspher
facilit
receptor
mediat
endocytosi
result
cellspecif
deliveri
vaccin
formul
synthes
biotinyl
chitosan
use
formul
pvaxn
load
nanoparticl
biotin
substitut
chitosan
backbon
facilit
attach
bifunct
fusion
protein
bffp
corestreptavidin
arm
scfv
arm
assist
guid
nanoparticl
toward
dc
n
protein
gene
clone
us
fda
approv
plasmid
vector
contain
cmv
promot
bgh
polyadenyl
sequenc
mammalian
protein
express
nanoencapsul
form
pvaxn
found
resist
nucleas
digest
follow
incub
dnase
vital
vivo
perform
nanoparticul
formul
intranas
applic
bffp
target
nanoparticul
vaccin
induc
system
mucos
immun
respons
n
protein
antigen
addit
mere
administr
nake
pdna
nanoencapsul
pdna
suffici
enough
provok
detect
serum
titer
n
protein
specul
could
due
lowdos
pvaxn
antigen
contemporari
studi
shown
immun
respons
follow
use
pdna
encapsul
chitosan
particl
high
dose
encapsul
pdna
frequent
dose
use
result
appar
system
mucos
n
protein
specif
respons
induc
mice
use
bffp
base
target
nanoencapsul
pvaxn
n
protein
specif
serum
igg
antibodi
elicit
higher
magnitud
target
formul
coadminist
dc
matur
activ
stimuli
anti
mab
splenocyt
capabl
produc
cytokin
upon
vitro
stimul
recombin
n
protein
howev
significantli
higher
level
detect
target
formul
compar
nontarget
formul
codeliveri
dc
matur
stimuli
target
formul
result
augment
level
irrespect
rout
immun
report
promis
strategi
enhanc
immunogen
lowdos
dna
vaccin
target
deliveri
nasal
resid
dendrit
cell
vaccin
strategi
demonstr
could
provid
better
understand
non
invas
mean
target
vaccin
antigen
dendrit
cell
antigen
formul
develop
warrant
evalu
sarscov
viru
challeng
experi
studi
import
implic
design
vaccin
sar
infect
similar
mechan
refer
web
version
pubm
central
supplementari
materi
schemat
represent
dendrit
cell
target
strategi
use
bifunct
fusion
protein
bffp
bffp
recombin
fusion
protein
consist
truncat
corestreptavidin
fuse
singl
chain
antibodi
scfv
corestreptavidin
arm
fusion
protein
bind
biotinyl
nanoparticl
scfv
impart
target
specif
dc
receptor
schemat
synthesi
biotinyl
chitosan
b
estim
chitosan
modif
use
fluorescamin
assay
extent
biotinyl
amin
group
chitosan
determin
use
fluorescamin
react
primari
amin
group
decreas
fluoresc
intens
proport
percentag
biotinyl
amin
group
analysi
timedepend
serum
igg
antibodi
sarscov
n
protein
follow
im
immun
differ
vaccin
formul
balbc
mice
mice
per
group
immun
pvaxn
day
day
mous
serum
collect
day
post
immun
igg
n
protein
detect
use
elisa
data
present
group
mean
sd
variou
timepoint
elisa
perform
dilut
sera
b
detect
n
protein
specif
serum
igg
isotyp
mice
vaccin
differ
formul
igg
isotyp
detect
serum
sampl
obtain
day
elisa
perform
dilut
sera
data
present
group
mean
sd
statist
differ
group
denot
p
ns
signific
differ
p
horizont
bar
compar
statist
differ
differ
group
sarscov
n
protein
specif
iga
level
nasal
wash
nasal
wash
collect
day
follow
euthanasia
assay
presenc
n
protein
specif
iga
use
elisa
sampl
analyz
triplic
data
repres
group
mean
sd
five
mice
statist
differ
group
denot
p
ns
signific
differ
p
horizont
bar
denot
statist
differ
iga
differ
group
compar
group
analysi
level
mice
immun
differ
vaccin
formul
splenocyt
obtain
group
immun
mice
mice
per
group
pool
cultur
presenc
recombin
n
protein
flat
bottom
plate
final
volum
ul
cultur
supernat
harvest
hr
analyz
level
use
elisa
kit
data
repres
mean
sd
triplic
cultur
stimul
n
protein
statist
differ
group
denot
p
denot
statist
differ
differ
group
level
obtain
follow
stimul
con
pgml
differ
group
wherea
detect
level
observ
splenocyt
cultur
stimul
media
alon
